Skip to main content
SpringerLink
Log in

Pharmacokinetic characterization of CK2 inhibitor CX-4945

  • Research Article
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

Over-expression of protein kinase CK2 is highly linked to the survival of cancer cells and the poor prognosis of patients with cancers. CX-4945, a potent and selective orally bioavailable ATP-competitive inhibitor of CK2, inhibits the oncogenic cellular events such as proliferation and angiogenesis, and the increase of tumor growth in mouse xenograft model. In this study, the pharmacokinetic information about CX-4945 was provided; at 10 μM, CX-4945 with high stability in human and rat liver microsome exhibited low percentage of inhibition (<10 %) in CYP450 isoforms (1A2, 2C19, 3A4), but considerable inhibition (~70 %) in CYP450 2C9 and 2D6. In hERG potassium channel inhibition assay, CX-4945 exhibited relatively low inhibition rate. Additionally, CX-4945 showed high MDCK cell permeability (>10 × 10−6 cm/s) and above 98 % of plasma protein binding in the rat. After intravenous administration, Vss (1.39 l/kg) and extremely low CL (0.08 l/kg/h) were observed. Moreover, orally administrated CX-4945 showed high bioavailability (>70 %) and these data might be related to the MDCK cell permeability results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Battistutta, R., E. De Moliner, S. Sarno, G. Zanotti, and L.A. Pinna. 2001. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Science 10: 2200–2206.

    Article  PubMed  CAS  Google Scholar 

  • Belardinelli, L., C. Antzelevitch, and M.A. Vos. 2003. Assessing predictors of drug-induced torsade de pointes. Trends in Pharmacological Sciences 24: 619–625.

    Article  PubMed  CAS  Google Scholar 

  • Buerra, B., and O.G. Issinger. 2008. Protein kinase CK2 in human diseases. Current Medicinal Chemistry 15: 1870–1886.

    Article  Google Scholar 

  • Drygin, D., C.B. Ho, M. Omori, J. Bliesath, C. Proffitt, R. Rice, A. Siddiqui-Jain, S. O’Brien, C. Padgett, J.K. Lim, K. Anderes, W.G. Rice, and D. Ryckman. 2011. Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer. Biochemical and Biophysical Research Communications 415: 163–167.

    Article  PubMed  CAS  Google Scholar 

  • Duncan, J.S., and D.W. Litchfield. 2008. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochimica et Biophysica Acta 1784: 33–47.

    Article  PubMed  CAS  Google Scholar 

  • Hung, M.S., Z. Xu, Y.C. Lin, J.H. Mao, C.T. Yang, P.J. Chang, D.M. Jablons, and L. You. 2009. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library. BMC Cancer 9: 135.

    Article  PubMed  Google Scholar 

  • Kim, J., and S.H. Kim. 2012. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond. Archives of Pharmacal Research 35: 1293–1296.

    Article  PubMed  CAS  Google Scholar 

  • Landesman-Bollag, E., R. Romieu-Mourez, D.H. Song, G.E. Sonenshein, R.D. Cardiff, and D.C. Seldin. 2001. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20: 3247–3257.

    Article  PubMed  CAS  Google Scholar 

  • Laramas, M., D. Pasquier, O. Filhol, F. Ringeisen, J.L. Descotes, and C. Cochet. 2007. Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. European Journal of Cancer 43: 928–934.

    Article  PubMed  CAS  Google Scholar 

  • Litchfield, D.W. 2003. Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochemical Journal 369: 1–15.

    Article  PubMed  CAS  Google Scholar 

  • Ljubimov, A.V., S. Caballero, A.M. Aoki, L.A. Pinna, M.B. Grant, and R. Castellon. 2004. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Investigative Ophthalmology & Visual Science 45: 4583–4591.

    Article  Google Scholar 

  • Lopez-Ramos, M., R. Prudent, V. Moucadel, C.F. Sautel, C. Barette, L. Lafanechere, L. Mouaawad, D. Grierson, F. Schmidt, J.C. Florent, P. Filippakopoulos, A.N. Bullock, S. Knapp, J.B. Reiser, and C. Cochet. 2010. New potent dual inhibitors of CK2 and Pim kinases: Discovery and structural insights. FASEB Journal 24: 3171–3185.

    Article  PubMed  CAS  Google Scholar 

  • Mottet, D., S.P. Ruys, C. Demazy, M. Raes, and C. Michiels. 2005. Role for casein kinase 2 in the regulation of HIF-1 activity. International Journal of Cancer 117: 764–774.

    Article  CAS  Google Scholar 

  • O-charoenrat, P., V. Rusch, and S.G. Talbot. 2004. Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clinical Cancer Research 10: 5792–5803.

    Article  PubMed  CAS  Google Scholar 

  • Pagono, M.A., J. Bain, Z. Kazimierczuk, S. Sarno, M.Di. Ruzzene, G. Maira, M. Elliott, A. Orzeszko, G. Cozza, F. Meggio, and L.A. Pinna. 2008. The selectivity of inhibitors of protein kinase CK2: An update. Biochemical Journal 415: 353–365.

    Article  Google Scholar 

  • Parhar, J., J. Morse, and B. Salh. 2007. The role of protein kinase CK2 in intestinal epithelial cell inflammatory signaling. International Journal of Colorectal Disease 22: 601–609.

    Article  PubMed  Google Scholar 

  • Park, J.S., M.S. Kim, J.S. Song, S.H. Choi, B.H. Lee, J. Woo, J.H. Ahn, M.A. Bae, and S.H. Ahn. 2011. Dose-independent pharmacokinetics of a new peroxisome proliferator-activated receptor-γ agonist, KR-62980, in Sprague-Dawley rats and ICR mice. Archives of Pharmacal Research 34: 2051–2058.

    Article  PubMed  CAS  Google Scholar 

  • Pierre, F., P.C. Chua, S.E. O’Brien, A. Siddiqui-Jain, P. Bourbon, M. Haddach, J. Michaux, J. Nagasawa, M.K. Schwaebe, E. Stefan, A. Vialettes, J.P. Whitten, T.K. Chen, L. Darjania, R. Stansfield, K. Anderes, J. Bliesath, D. Drygin, C. Ho, M. Omori, C. Proffitt, N. Streiner, K. Trent, W.G. Rice, and D.M. Ryckman. 2011. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]-naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. Journal of Medicinal Chemistry 5: 635–654.

    Article  Google Scholar 

  • Pistorius, K., G. Seitz, K. Remberger, and O.G. Issinger. 1991. Differential CKII activities in human colorectal mucosa, adenomas and carcinomas. Onkologie 14: 256–260.

    Article  Google Scholar 

  • Redfern, W.S., L. Carlsson, A.S. Davis, W.G. Lynch, I. Mackenzie, and S. Palethoroe. 2003. Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovascular Research 58: 32–45.

    Article  PubMed  CAS  Google Scholar 

  • Rendic, S., and F.J. Di Carlo. 1992. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews 29: 413–580.

    Article  Google Scholar 

  • Rodrigues, A.D. 1999. Integrated P450 reaction phenotyping: Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochemical Pharmacology 57: 465–480.

    Article  PubMed  CAS  Google Scholar 

  • Ruiz-Garcia, A., M. Bermejo, A. Moss, and V.G. Casabo. 2008. Pharmacokinetics in drug discovery. Journal of Pharmaceutical Sciences 97: 654–690.

    Article  PubMed  CAS  Google Scholar 

  • Ruzzene, M., and L.A. Pinna. 2010. Addition to protein kinase CK2: A common denominator of diverse cancer cells? Biochimica et Biophysica Acta 1804: 499–504.

    Article  PubMed  CAS  Google Scholar 

  • Sandholt, I.S., B.B. Olsen, B. Guerra, and O.G. Issinger. 2009. Resorufin: A lead for a new protein kinase CK2 inhibitor. Anti-Cancer Drugs 20: 238–248.

    Article  PubMed  CAS  Google Scholar 

  • Sarno, S., and L.A. Pinna. 2008. Protein kinase CK2 as a druggable target. Molecular BioSystems 4: 889–894.

    Article  PubMed  CAS  Google Scholar 

  • Seldin, D.D., and P. Leder. 1995. Casein kinase II alpha transgene-induced murine lymphoma: Relation to theileriosis in cattle. Science 267: 894–897.

    Article  PubMed  CAS  Google Scholar 

  • Siddiqui-Jain, A., D. Drygin, N. Streiner, P. Chua, F. Pierre, S.E. O’Brien, J. Blesath, M. Omori, N. Huser, C. Ho, C. Proffitt, M.K. Schwaebe, D.M. Ryckman, W.G. Rice, and K. Andres. 2010. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Research 70: 10288–10298.

    Article  PubMed  CAS  Google Scholar 

  • Slaton, J.W., G.M. Unger, D.T. Sloper, A.T. Davis, and K. Ahmed. 2004. Introduction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Molecular Cancer Research 2: 712–721.

    PubMed  CAS  Google Scholar 

  • Song, J.S., J.W. Chae, K.R. Lee, B.H. Lee, E.J. Choi, S.H. Ahn, K.I. Kwon, and M.A. Bae. 2011a. Pharmacokinetic characterization of decursinol derived from Angelica gigas Nakai in rats. Xenobiotica 41: 895–902.

    Article  PubMed  CAS  Google Scholar 

  • Song, J.S., H.J. Rho, J.S. Park, M.S. Kim, B.H. Lee, J.W. Seo, D.J. Jeon, H.G. Cheon, S.H. Ahn, K.I. Kwon, and M.A. Bae. 2011b. Preclinical pharmacokinetics of PDE-310, a novel PDE4 inhibitor. Drug Metabolism and Pharmacokinetics 26: 192–200.

    Article  PubMed  CAS  Google Scholar 

  • Stalter, G., S. Siemer, E. Becht, M. Ziegler, K. Remberger, and O.G. Issinger. 1994. Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochemical and Biophysical Research Communications 202: 141–147.

    Article  PubMed  CAS  Google Scholar 

  • Thummel, K.E., and G. Wilkinson. 1998. In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 38: 370–381.

    Google Scholar 

  • van Golen, K.L., Z.F. Wu, X.T. Qiao, L. Bao, and S.D. Merajver. 2000. RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. Neoplasia 2: 418–425.

    Article  PubMed  Google Scholar 

  • Wang, G., G. Unger, K.A. Ahmad, J.W. Slaton, and K. Ahmed. 2005. Downregulation of CK2 induces apoptosis in cancer cells—A potential approach to cancer therapy. Molecular and Cellular Biochemistry 274: 77–84.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by KRICT’s project, SI-1304 funded by the Ministry of Knowledge Economy, Republic of Korea.

Author information

Authors and Affiliations

  1. Laboratory of Translational Therapeutics, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong-gu, Daejeon, 305-600, Republic of Korea

    You Hwa Son, Seong Hwan Kim & Jiyeon Kim

  2. Drug Discovery Platform Technology Team, Bio-Organic Science Division, Korea Research Institute of Chemical Technology, P.O. Box 107, Yuseong-gu, Daejeon, 305-600, Republic of Korea

    Jin Sook Song

Authors
  1. You Hwa Son
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jin Sook Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seong Hwan Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiyeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Seong Hwan Kim or Jiyeon Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Son, Y.H., Song, J.S., Kim, S.H. et al. Pharmacokinetic characterization of CK2 inhibitor CX-4945. Arch. Pharm. Res. 36, 840–845 (2013). https://doi.org/10.1007/s12272-013-0103-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-013-0103-9

Keywords

Search

Navigation